| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft vs Host Disease | 45 | 2024 | 2808 | 7.980 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 73 | 2024 | 7017 | 7.920 |
Why?
|
| Unrelated Donors | 13 | 2024 | 321 | 4.370 |
Why?
|
| Leukemia, Myeloid, Acute | 30 | 2024 | 7264 | 2.670 |
Why?
|
| Histocompatibility Testing | 9 | 2024 | 487 | 2.670 |
Why?
|
| Cyclophosphamide | 16 | 2024 | 3244 | 2.650 |
Why?
|
| Donor Selection | 4 | 2024 | 110 | 2.160 |
Why?
|
| Siblings | 4 | 2024 | 319 | 1.990 |
Why?
|
| HLA Antigens | 8 | 2024 | 594 | 1.920 |
Why?
|
| Transplantation Conditioning | 25 | 2024 | 2368 | 1.910 |
Why?
|
| Killer Cells, Natural | 10 | 2020 | 965 | 1.690 |
Why?
|
| Myeloablative Agonists | 5 | 2022 | 386 | 1.650 |
Why?
|
| Cord Blood Stem Cell Transplantation | 9 | 2020 | 372 | 1.630 |
Why?
|
| Tissue Donors | 6 | 2024 | 815 | 1.540 |
Why?
|
| Hematologic Neoplasms | 12 | 2020 | 1955 | 1.500 |
Why?
|
| Receptors, KIR | 4 | 2018 | 64 | 1.450 |
Why?
|
| Busulfan | 11 | 2023 | 792 | 1.400 |
Why?
|
| Fetal Blood | 7 | 2020 | 501 | 1.270 |
Why?
|
| Mycophenolic Acid | 3 | 2024 | 153 | 1.200 |
Why?
|
| Transplantation, Haploidentical | 7 | 2024 | 159 | 1.040 |
Why?
|
| Tacrolimus | 3 | 2022 | 347 | 1.020 |
Why?
|
| Myelodysplastic Syndromes | 11 | 2024 | 3155 | 1.000 |
Why?
|
| Cytomegalovirus Infections | 3 | 2024 | 495 | 0.960 |
Why?
|
| Poisons | 1 | 2023 | 9 | 0.910 |
Why?
|
| Recurrence | 18 | 2023 | 4877 | 0.880 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2018 | 1840 | 0.860 |
Why?
|
| Multiple Myeloma | 10 | 2024 | 2281 | 0.820 |
Why?
|
| Humans | 108 | 2024 | 270880 | 0.810 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2023 | 2903 | 0.810 |
Why?
|
| Aged | 59 | 2024 | 73417 | 0.800 |
Why?
|
| Middle Aged | 59 | 2024 | 90382 | 0.780 |
Why?
|
| Young Adult | 31 | 2024 | 22245 | 0.760 |
Why?
|
| Adult | 51 | 2024 | 82036 | 0.730 |
Why?
|
| Age Factors | 8 | 2024 | 5465 | 0.720 |
Why?
|
| Allografts | 9 | 2024 | 686 | 0.720 |
Why?
|
| Transplantation, Homologous | 16 | 2024 | 3044 | 0.720 |
Why?
|
| Photopheresis | 1 | 2021 | 79 | 0.710 |
Why?
|
| Adolescent | 30 | 2024 | 32770 | 0.630 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2018 | 683 | 0.630 |
Why?
|
| Vidarabine | 9 | 2022 | 1383 | 0.610 |
Why?
|
| Male | 60 | 2024 | 128463 | 0.610 |
Why?
|
| Stem Cell Transplantation | 6 | 2023 | 1414 | 0.560 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2018 | 1367 | 0.550 |
Why?
|
| Female | 59 | 2024 | 149029 | 0.550 |
Why?
|
| Graft Survival | 2 | 2017 | 1082 | 0.540 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 164 | 0.540 |
Why?
|
| Histocompatibility | 4 | 2024 | 183 | 0.520 |
Why?
|
| Neutrophils | 2 | 2017 | 873 | 0.500 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2017 | 205 | 0.500 |
Why?
|
| Hematologic Diseases | 1 | 2016 | 255 | 0.470 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 431 | 0.470 |
Why?
|
| Myeloid Cells | 1 | 2016 | 273 | 0.470 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2013 | 36 | 0.450 |
Why?
|
| Disease-Free Survival | 10 | 2022 | 10260 | 0.450 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2018 | 593 | 0.450 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2013 | 107 | 0.440 |
Why?
|
| Thyroid Nodule | 1 | 2013 | 92 | 0.420 |
Why?
|
| Maintenance Chemotherapy | 3 | 2024 | 224 | 0.410 |
Why?
|
| Lower Gastrointestinal Tract | 2 | 2023 | 29 | 0.410 |
Why?
|
| Retrospective Studies | 24 | 2024 | 39865 | 0.400 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2023 | 94 | 0.400 |
Why?
|
| Whole-Body Irradiation | 3 | 2019 | 323 | 0.390 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2016 | 714 | 0.380 |
Why?
|
| Survival Rate | 12 | 2024 | 12538 | 0.370 |
Why?
|
| Genotype | 1 | 2018 | 4255 | 0.360 |
Why?
|
| Steroids | 3 | 2021 | 372 | 0.350 |
Why?
|
| Thalidomide | 1 | 2013 | 595 | 0.350 |
Why?
|
| Melphalan | 5 | 2020 | 875 | 0.350 |
Why?
|
| Immunologic Factors | 1 | 2013 | 672 | 0.340 |
Why?
|
| Child, Preschool | 10 | 2024 | 17059 | 0.330 |
Why?
|
| Leukemia, Plasma Cell | 2 | 2019 | 42 | 0.320 |
Why?
|
| Bone Marrow | 5 | 2021 | 2439 | 0.320 |
Why?
|
| Cytomegalovirus | 2 | 2024 | 496 | 0.310 |
Why?
|
| Immunosuppressive Agents | 3 | 2024 | 1431 | 0.300 |
Why?
|
| Child | 14 | 2024 | 30568 | 0.290 |
Why?
|
| Prospective Studies | 8 | 2024 | 13420 | 0.280 |
Why?
|
| Acute Disease | 5 | 2024 | 2496 | 0.260 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2020 | 2486 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 16670 | 0.250 |
Why?
|
| Treatment Outcome | 21 | 2024 | 33756 | 0.250 |
Why?
|
| Transplantation, Autologous | 8 | 2021 | 2045 | 0.250 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2024 | 980 | 0.240 |
Why?
|
| Return to Work | 1 | 2024 | 17 | 0.230 |
Why?
|
| HLA-DRB1 Chains | 1 | 2024 | 89 | 0.230 |
Why?
|
| Bacteroides | 1 | 2024 | 54 | 0.230 |
Why?
|
| Toxoplasmosis | 1 | 2024 | 49 | 0.220 |
Why?
|
| Complement Inactivating Agents | 1 | 2023 | 17 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 10395 | 0.220 |
Why?
|
| Complement C5a | 1 | 2023 | 35 | 0.220 |
Why?
|
| Infant | 7 | 2024 | 13997 | 0.210 |
Why?
|
| Endophthalmitis | 1 | 2023 | 82 | 0.210 |
Why?
|
| Immunotherapy | 1 | 2016 | 3557 | 0.210 |
Why?
|
| Benzoates | 1 | 2024 | 128 | 0.210 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2022 | 838 | 0.210 |
Why?
|
| Thyroid Neoplasms | 1 | 2013 | 1894 | 0.210 |
Why?
|
| Primary Myelofibrosis | 2 | 2021 | 914 | 0.200 |
Why?
|
| Chronic Disease | 3 | 2024 | 1829 | 0.200 |
Why?
|
| Prognosis | 14 | 2024 | 22501 | 0.200 |
Why?
|
| Hydrazines | 1 | 2024 | 213 | 0.200 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 29 | 0.190 |
Why?
|
| Lymphocyte Activation | 2 | 2016 | 1723 | 0.190 |
Why?
|
| Transplant Recipients | 2 | 2020 | 336 | 0.190 |
Why?
|
| Hemorrhagic Disorders | 1 | 2021 | 52 | 0.190 |
Why?
|
| Acetamides | 1 | 2021 | 111 | 0.190 |
Why?
|
| Neoplasms | 4 | 2022 | 15933 | 0.180 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2020 | 381 | 0.170 |
Why?
|
| Cystitis | 1 | 2021 | 109 | 0.170 |
Why?
|
| Mortality | 3 | 2018 | 347 | 0.170 |
Why?
|
| Induction Chemotherapy | 2 | 2023 | 670 | 0.170 |
Why?
|
| Myelitis, Transverse | 1 | 2019 | 13 | 0.170 |
Why?
|
| Quality of Life | 2 | 2024 | 4775 | 0.170 |
Why?
|
| Intervertebral Disc Degeneration | 1 | 2019 | 22 | 0.170 |
Why?
|
| Thyroglobulin | 1 | 2019 | 65 | 0.170 |
Why?
|
| Mothers | 1 | 2022 | 416 | 0.170 |
Why?
|
| Nervous System Diseases | 1 | 2023 | 517 | 0.160 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2020 | 214 | 0.160 |
Why?
|
| Optic Neuritis | 1 | 2019 | 38 | 0.160 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2018 | 22 | 0.160 |
Why?
|
| Survival Analysis | 9 | 2021 | 9290 | 0.160 |
Why?
|
| Methotrexate | 1 | 2022 | 1025 | 0.160 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2020 | 135 | 0.160 |
Why?
|
| Alemtuzumab | 1 | 2019 | 213 | 0.160 |
Why?
|
| Lung Transplantation | 1 | 2023 | 383 | 0.160 |
Why?
|
| Antilymphocyte Serum | 2 | 2020 | 237 | 0.160 |
Why?
|
| Delayed Graft Function | 1 | 2018 | 7 | 0.160 |
Why?
|
| Clonal Evolution | 1 | 2020 | 250 | 0.160 |
Why?
|
| Survivors | 1 | 2024 | 1023 | 0.150 |
Why?
|
| Neutropenia | 1 | 2022 | 1006 | 0.150 |
Why?
|
| Immune Reconstitution | 1 | 2018 | 25 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2019 | 287 | 0.150 |
Why?
|
| Blast Crisis | 1 | 2021 | 587 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2019 | 413 | 0.150 |
Why?
|
| Pentostatin | 1 | 2017 | 121 | 0.150 |
Why?
|
| Haplotypes | 2 | 2018 | 910 | 0.150 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2024 | 1347 | 0.150 |
Why?
|
| Azacitidine | 1 | 2024 | 1218 | 0.140 |
Why?
|
| Niacinamide | 1 | 2018 | 428 | 0.140 |
Why?
|
| Proportional Hazards Models | 3 | 2023 | 5102 | 0.140 |
Why?
|
| Antigens, CD34 | 1 | 2018 | 639 | 0.140 |
Why?
|
| Virus Activation | 1 | 2018 | 236 | 0.140 |
Why?
|
| Antigens, CD19 | 1 | 2020 | 584 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2021 | 4961 | 0.140 |
Why?
|
| B-Lymphocytes, Regulatory | 1 | 2016 | 23 | 0.140 |
Why?
|
| Epistasis, Genetic | 1 | 2016 | 120 | 0.130 |
Why?
|
| B-Lymphocytes | 3 | 2019 | 1424 | 0.130 |
Why?
|
| Genetic Engineering | 1 | 2018 | 295 | 0.130 |
Why?
|
| France | 1 | 2016 | 122 | 0.130 |
Why?
|
| Follow-Up Studies | 6 | 2021 | 15223 | 0.130 |
Why?
|
| Premedication | 1 | 2016 | 133 | 0.130 |
Why?
|
| Lymphoma, Follicular | 1 | 2021 | 636 | 0.130 |
Why?
|
| Bayes Theorem | 1 | 2021 | 1060 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 1020 | 0.130 |
Why?
|
| Immunity, Humoral | 1 | 2016 | 88 | 0.130 |
Why?
|
| Incidence | 4 | 2020 | 5829 | 0.130 |
Why?
|
| Risk Factors | 7 | 2024 | 17902 | 0.130 |
Why?
|
| Bone Marrow Transplantation | 2 | 2024 | 1757 | 0.130 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 1013 | 0.120 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 151 | 0.120 |
Why?
|
| Bone Marrow Cells | 1 | 2019 | 968 | 0.120 |
Why?
|
| Fucose | 1 | 2015 | 58 | 0.120 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 929 | 0.120 |
Why?
|
| Pyrazoles | 1 | 2024 | 1546 | 0.120 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 1101 | 0.120 |
Why?
|
| Autoantigens | 1 | 2016 | 248 | 0.120 |
Why?
|
| Risk Assessment | 3 | 2022 | 6769 | 0.120 |
Why?
|
| Coculture Techniques | 1 | 2016 | 628 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2016 | 255 | 0.120 |
Why?
|
| Translocation, Genetic | 1 | 2019 | 1285 | 0.110 |
Why?
|
| Interleukin-10 | 1 | 2016 | 484 | 0.110 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2019 | 1144 | 0.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 1062 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 1067 | 0.110 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 9039 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 1387 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6255 | 0.110 |
Why?
|
| Myeloproliferative Disorders | 1 | 2021 | 882 | 0.110 |
Why?
|
| Lymphatic Diseases | 1 | 2013 | 127 | 0.110 |
Why?
|
| Chromosome Aberrations | 1 | 2020 | 2031 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 714 | 0.110 |
Why?
|
| Remission Induction | 4 | 2020 | 3652 | 0.110 |
Why?
|
| Propensity Score | 3 | 2021 | 771 | 0.100 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2013 | 107 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2022 | 1933 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 14617 | 0.100 |
Why?
|
| Time Factors | 4 | 2021 | 13023 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2016 | 700 | 0.100 |
Why?
|
| Interferon-gamma | 1 | 2016 | 1180 | 0.100 |
Why?
|
| Virus Diseases | 1 | 2015 | 392 | 0.090 |
Why?
|
| Models, Biological | 1 | 2019 | 3196 | 0.090 |
Why?
|
| Blood Platelets | 1 | 2015 | 677 | 0.090 |
Why?
|
| Lymphoma | 1 | 2019 | 1520 | 0.090 |
Why?
|
| Patient Selection | 1 | 2017 | 2026 | 0.090 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2013 | 689 | 0.090 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 3944 | 0.090 |
Why?
|
| Autografts | 2 | 2021 | 179 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2017 | 2122 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 3408 | 0.080 |
Why?
|
| Alleles | 1 | 2015 | 2602 | 0.080 |
Why?
|
| Aged, 80 and over | 6 | 2023 | 31037 | 0.080 |
Why?
|
| Feasibility Studies | 3 | 2020 | 2364 | 0.080 |
Why?
|
| Mutation | 4 | 2022 | 15911 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2016 | 5698 | 0.070 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2019 | 2634 | 0.070 |
Why?
|
| Transcriptome | 1 | 2016 | 1960 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 4894 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 2 | 2024 | 607 | 0.070 |
Why?
|
| Retreatment | 2 | 2019 | 447 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 3657 | 0.060 |
Why?
|
| Bacteroides thetaiotaomicron | 1 | 2024 | 17 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 2196 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2020 | 2308 | 0.060 |
Why?
|
| Comorbidity | 2 | 2023 | 2394 | 0.060 |
Why?
|
| Gene Dosage | 2 | 2018 | 823 | 0.060 |
Why?
|
| Research Design | 2 | 2024 | 1569 | 0.060 |
Why?
|
| Minnesota | 1 | 2024 | 126 | 0.060 |
Why?
|
| Dysbiosis | 1 | 2024 | 152 | 0.050 |
Why?
|
| Neoplasm, Residual | 2 | 2019 | 1752 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2022 | 26 | 0.050 |
Why?
|
| Propionates | 1 | 2022 | 75 | 0.050 |
Why?
|
| Mucus | 1 | 2022 | 109 | 0.050 |
Why?
|
| Risk | 2 | 2018 | 1940 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2024 | 6237 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2024 | 216 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 3440 | 0.050 |
Why?
|
| Mucins | 1 | 2022 | 289 | 0.050 |
Why?
|
| rho-Associated Kinases | 1 | 2021 | 80 | 0.050 |
Why?
|
| Chimerism | 1 | 2021 | 65 | 0.050 |
Why?
|
| Transplantation Chimera | 1 | 2021 | 173 | 0.050 |
Why?
|
| Feces | 1 | 2024 | 861 | 0.050 |
Why?
|
| Spirometry | 1 | 2020 | 153 | 0.040 |
Why?
|
| Azithromycin | 1 | 2020 | 79 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2021 | 179 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2024 | 2455 | 0.040 |
Why?
|
| Biopsy | 2 | 2020 | 3485 | 0.040 |
Why?
|
| Retroviridae | 1 | 2020 | 373 | 0.040 |
Why?
|
| Disease Progression | 2 | 2024 | 6865 | 0.040 |
Why?
|
| Ascites | 1 | 2020 | 213 | 0.040 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 10707 | 0.040 |
Why?
|
| Chromosomes | 1 | 2019 | 324 | 0.040 |
Why?
|
| Immunologic Surveillance | 1 | 2018 | 59 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 574 | 0.040 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 282 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 7784 | 0.040 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2022 | 460 | 0.040 |
Why?
|
| Bortezomib | 1 | 2019 | 543 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2018 | 574 | 0.030 |
Why?
|
| Philadelphia Chromosome | 1 | 2021 | 852 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2022 | 2345 | 0.030 |
Why?
|
| Histocompatibility Antigens | 1 | 2015 | 79 | 0.030 |
Why?
|
| Dasatinib | 1 | 2019 | 881 | 0.030 |
Why?
|
| Fucosyltransferases | 1 | 2015 | 78 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 106 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2019 | 1691 | 0.030 |
Why?
|
| P-Selectin | 1 | 2015 | 110 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1480 | 0.030 |
Why?
|
| Platelet Transfusion | 1 | 2015 | 166 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2020 | 1857 | 0.030 |
Why?
|
| Cytokines | 1 | 2023 | 2826 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2019 | 1507 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 4499 | 0.030 |
Why?
|
| Reoperation | 1 | 2018 | 1392 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 14012 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 2518 | 0.030 |
Why?
|
| Animals | 3 | 2024 | 62051 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 7103 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 2015 | 520 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2013 | 203 | 0.030 |
Why?
|
| Mice | 2 | 2024 | 35598 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2017 | 602 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 3300 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2019 | 3145 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 5927 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 1052 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 7386 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 5070 | 0.020 |
Why?
|
| Brain | 1 | 2023 | 4213 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 6194 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 4963 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 3845 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 2453 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 5060 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 5404 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 3642 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 9475 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 7665 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2016 | 12103 | 0.010 |
Why?
|